Get inspired
PUBLICATIONS
Since the center inauguration, participants in the center have consistently published their research findings and conclusions in international renowned journals. The ctDNA Center has international collaborations with both academic and commercial partners, actively participation in various international networks and societies focused on ctDNA. We prioritize sharing our findings and results both publicly and within the research community,
Find the scientific publications below.
Popular science articles
Find articles in news media here
143. ASO Author Reflections: Potential of Circulating Tumor DNA in Stratifying Patients with Localized pMMR Colon Cancer to Neoadjuvant Therapy
Henry G. Smith, Tenna V. Henriksen, Claus L. Andersen.
(2026, July). Annals of Surgical Oncology. DOI: 10.1245/s10434-026-19682-2. PMID: 42002707
142. Prognostic significance of circulating tumor DNA as a baseline or dynamic factor in advanced NSCLC without oncogenic drivers: A systematic review and meta-analysis
M. E. Andersen, E. M. Hedegaard, S. W. C. Wen, L. B. Callesen, W. M. Szejniuk, M. Ladekarl, S. Timm, K. G. Spindler, M. S. Frank.
(2026, May). Clritical reviews in oncology/hematology. DOI: 10.10.16/j.critrevonv.2026.105226. PMID: 41724339
141. Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma
Cecilie Riis Iden, Nadia Øgaard, Salah Mohammad Mustafa, Ida Coordt Elle, Mette Yilmaz, Marianne Nordsmark, Tenna Henriksen, Torben Kruse, Mads Thomassen, Per Pfeiffer, Claus Lindbjerg Andersen, Lene Bæksgaard, Camilla Qvortrup, Morten Mau-Sørensen.
(2026, May). Gastric Cancer. DOI: 10.1007/s10120-026-01743-w PMID: 42176235
140. Neoadjuvant Signle-Cycle Penbrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial
Ismail Gögenur, Tobias F. Justesen, Line S. Tarpgaard, Mustafa Bulut, Torben F. Hansen, Lars H. Jensen, Hans B. Rahr, Mikail Gögenur, Tove Kirkegaard, Lukas Balsevicius, Michael Chieng, Hans Raskov, Mia K. S. Sørensen, Peter C. Petersen, Jens r. Eriksen, Søren Salomon, Anne-Marie K. Fiehn, Maria Dalgaard Mikkelsen, Søren Brandsborg, Kåre A. Gotschalck, Katrine J. Emmertsen, Anne Ramlov, Pernille W. Born, Ole Thorlacius-Ussing, Michael B. Lauritzen, René K. Olesen, Larurids Ø. Poulsen, Jakob Lykke, Jakob Schou, Laura Buskov, Peter-Martin Krarup, Claus L. Andersen, Niels Pallisgaard, Per Pfeiffer, Camilla Qvortrup.
(2026, May). Journal of Clinical Oncology; JCO2502274. DOI: 10.1200/JCO-25-02274. PMID: 42085635
139. Evaluation and verification of cfDNA extraction methods
Cecilie Mondrup Jacobsen, Luisa Matos do Canto, Estrid Høgdall, Rikke Fredslund Andersen.
(2026, May). Biotechniques; 78(1-12):1-4. DOI: 10.1080/07366205.2026.2665280. PMID: 42077088
138. Effect of one or two cycles of dual immunotherapy with nivolumab and ipilimumab in patients with mismatch repair-deficient rectal caner (RESET-R): Interim results from a multicentre, single-arm, phase 2 trial
Line Schmidt Tarpgaard, Laurids Østergaard Poulsen, Ismail Gögenur, Tobias Freyberg Justesen, Søren Rafael Rafaelsen, Nadia Øgaard, Christina Demuth, Claus Lindbjerg Andersen, Lise Ventzel, Pernille Øhlenschläger Larsen, Anne Ramlov, Ken Ljungmann, Michael Bødker Lauritzen, Laura Vittrup Diness, Jakob Lykke, Vinicius Araújo Barbosa de Lima, Søren Kjær, Søren Salomon, Per Vadgaard Andersen, Per Pfeiffer.
(2026, April). The Lancet, Gastroenterology and Hepatology. DOI: 10.1016/S2468-1253(26)00047-6. PMID: 42066786
137. Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer
Karoline Kondrup, Laura Iisaer, Paul Vinu Salachan, Maibritt Nørgaard, Philippe Lamy, Rosalind Eeles, Torben Frøstrup Hansen, Palle Jörn Sloth Osther, Ahmed Hussein Zedan, Michael Borre, Karina Dalsgaard Sørensen.
(2026, April). British Journal of Cancer. DOI: 10.1038/s41416-026-03432-y. PMID: 41963595
136. Potential of Circulating Tumor DNA in Stratifying Patients with Localized pMMR Colon Cancer to Neoadjuvant Therapy
Henry G. Smith, Tenna V. Henriksen, Claus Lindbjerg Andersen, IMPROVE Study Consortium.
(2026, April). Annals of Surgical Oncology. DOI: 10.1245/s10434-026-19539-8. PMID: 41933244
135. Cell-Free DNA-Derived Immune Cell Ratios Uncover Cancer-Associated Systematic Changes
Laura Andersen, Sia V. Lindskrog, Iver Nordentoft, Amanda Frydendahl, Jesper Nors, Tenna V. Henriksen, Mads H. Rasmussen, Lene H. Iversen, Kåre A. Gotschalck, Jørgen B. Jensen, Lars Dyrskjøt, Claus L. Andersen, Nicolai J. Birkbak.
(2026, April). Cancer Research Communications; 6(4):811-820. DOI: 10.1158/2767-9764.CRC-25-0747. PMID: 41881575
134. Perspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology
Miarus Ilié. Umberto Malapelle, Catherine Alix-Panabières, Claus Lindbjerg Andersen, Sandra Chlebowski, Vivien Lake, Caroline Lacoux, Virginie Lespinet-Fabre, Olivier Bordone, Simon Heeke, Christophe Bontoux, Ellen Heitzer, Klaus Pantel, Paul Hofman.
(2026, April). Molecular Oncology; 20(4):894-903. DOI: 10.1002/1878-0261.70163. PMID: 41235697
133. Bevacizumab and Tocotrienol in Recurrent Platinum-Resistant Ovarian Cancer, and the Role of HOXA9 as a Prognostic Biomarker
Elisabeth Emanuel Graae, Louise Faaborg, Rikke Fredslund Andersen, Lars Ulrik Fokdal, Caroline Brenner Thomsen.
(2026, March). Diseases; 14(3):104. DOI: 10.33907diseases1403104. PMID: 41892005
132. The prognostic value of methylated ctDNA, soluble PD-L1, and NK-cell activity on the risk of relapse after curative radiotherapy of non-small cell lung cancer
Thomas Leth Fink, Rikke Fredslund Andersen, Cecilie Mondrup Jacobsen, Line Nederby, Mads Malik Aagaard Jørgensen, Charlotte Kristiansen, Thorben Schjødt Hansen, Sara Witting Christensen Wen, Christa Haugaard Nyhus, Rune Slot Thing, Signe Timm, Torben Frøstrup Hansen.
(2026, March). Clinical and Translational Oncolog. DOI: 10.1007/s12094-026-04317-5. PMID: 41840317
131. Systematic review and meta-analysis of studies assessing circulating tumor DNA kinetics in metastatic colorectal cancer
L. B. Callesen, K-L. G. Spindler.
(2026, March). ESMO Gastrointestinal Oncology; 11:100314. DOI: 10.1016/j.esmogo.2026.100314. PMID: 41809060
130. Molecular residual disease assessment in colorectal and bladder cancer by somatic structural variant analysis of cell-free DNA whole-genome sequencing data
Ester Ellegaard Sørensen, Amanda Frydendahl, Mads Heilskov Rasmussen, Iver Nordentoft, Michael Knudsen, Tenna Vesterman Henriksen, Sia Viborg Lindskrog, Lars Dyrskjøt, Claus Lindbjerg Andersen, Jesper Bertram Bramsen.
(2026, February). Journal of Translational Medicine; 24(1): 364. DOI: 10.1186/s12968-026-07762-6. PMID: 41664150
129. ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: A nationwide Danish, randomised, intervention study (PRELUCA - PRediction in LUng CAncer Treatment) - study protocol
Michael Elmkvist Andersen, Christa Haugaard Nyhus, Weronika Maria Szejniuk, Stine Wahlstrøm, Signe Timm, Niels Pallisgaard, Malene Green Madsen, Maira Dalgaard Mikkelsen, Lise Barlebo Ahlborn, Julie Gehl, Malene Støchkel Frank.
(2026, February). BMJ Open; 16(2):e100311. DOI: 10.1136/bmjopen-2025-100311. PMID: 41628935
128. The prognostic value of cell-free DNA dynamics dyring chemoradiotherapy in squamous cell carcinomas of the anus
Anne Vittrup Jakobsen, Camilla Kronborg, Anne Ramlov, Christian Andreas Hvid, Karen-Lise Garm Spindler.
(2026, February). International Journal of Cancer; 158(3):790-798. DOI: 10.1002/ijc.70156. PMID: 40985905
127. Methylation-specific, universal, and highly sensitive identification of ctDNA in prostate cancer by multiplex droplet digital PCR
Søren Kahns, Ahmed H. Zedan, Mads M. Aagaard, Luisa M. D. Canto, Sanne Kjær-Friheldt, Stine V. Eriksen, Christine V. Madsen, Jonna S. Madsen, Palle J. S. Osther, Torben F. Hansen, Rikke F. Andersen.
(2026, January). PLoS One; 21(1):e0340786. DOI: 10.1371/jounal.pone.0340786. PMID: 41610073
126. ctDNA-guided treatment decisions in muscle-invasive bladder cancer
Lars Dyrskjøt.
(2026, January). Nature Reviews, Urology. DOI: 10.1038/s41585-026-01124-y. PMID: 41571955
125. Preoperative positive ctDNA analysis is associated with the tumor microenvironment, and the risk of recurrence in non-metastatic colorectal cancer
Mikail Gögenur, Lukas Balsevicius, Sarah Østrup Jensen, Nadia Øgaard, Iben Lyskjær, Tobias Freyberg Justesen, Michael Bzorek, Anne-Marie Kanstrup Fiehn, Line Rosell Walker, Rasmus Dahlin Bojesen, Andreas Weinberger Rosen, Claus Lindbjerg Andersen, Ismail Gögenur.
(2026, January). NPJ Precision Oncology; 10(1):76. DOI: 10.1038/s41698-026-01288-2. PMID: 41565913
124. Circulating tumor DNA in the diagnosis of ovarian cancer: A systematic review
Cristina Taliento, Pantaleo Greco, Giulia Bruni, Ina Marie Dueholm Hjort, An Coosemans, Wouter Froyman, Dirk TImmerman, John Charles Rotondo, Chiara Mazziotta, Martina Arcieri, Stefano Restaino, Francesco Multinu, Giuseppe Vizzielli, Carlotta Giorgi, Lars Dyrskjøt, Paolo Pinton, Giampaolo Morciano.
(2026, January). International Journal of Gynecological Cancer: 102686. DOI: 10.1016/j.ijgc.2025.102686. PMID: 41136311
123. ctDNA-Guided Immunotherapy following Radical Cystectomy for Muscle-Invasive Bladder Cancer: Results from the TOMBOLA trial
Lars Dyrskjøt, K. Birkenkamp-Demtröder, I. Nordentoft, T. Strandgaard, S. V. Lindskrog, R. V. Milling, S. K. Körner, S. B. Brandt, M. Knudsen, T. G. Andreasen, C. F. Hansen, P. Lamy, G. Lam, L. H. Dohn, K. Fabrin, A. Carus, A. C. Petersen, U. N. Joensen, H. Pappot, P. S. Holt, N. V. Jensen, M. Agerbæk, J. B. Jensen.
(2026, January). Annals of Oncology: S0923-7534(26)00011-6. DOI: 10.1016/j.annonc.2025.12.018. PMID: 41544704
122. Digital PCR Analysis of Methylated Circulating Tumor DNA
Rikke Fredslund Andersen, Tina Brandt Christensen, Torben Frøstrup Hansen.
(2026, January). Methods in Molecular Biology; 2969:123-133. DOI: 10.1007/978-1-0716-4767-7_8. PMID: 41073862
121. Clinical utility of longitudinal ctDNA monitoring by multiplex MS-ddPCR for risk stratification and follow-up in rectal cancer
Edina D. Lauridsen, Luisa Matos Do Canto, Signe TImm, Birgitte M. Havelund, Jan Lindebjerg, Lars Henrik Jensen, Rikke Fredslund Andersen, Torben Frøstrup Hansen.
(2026, January). International Journal of Colorectal Disease; 41(1):16. DOI: 10.1007/s00384-025-05055-w. PMID: 41484474
120. The Impact of Kidney, Liver, and Immune Function on Circulating Tumor DNA Detection in Muscle-invasive Bladder Cancer
Deema Radif, Sia Viborg Lindskrog, Iver Nordentoft, Karin Birkenkamp-Demtröder, Jørgen Bjerggaard Jensen, Mads Agerbæk, Lars Dyrskjøt.
(2025, December). European Urology Oncology; 8(6):1598-1606. DOI: 10.1010/j.euo.2025.09.012. PMID: 4107366
119. Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma
Trine Aaquist, Tenna Vesterman Henriksen, Lea Lecenda Mariager Jakobsen, Claus Wilki Fristrup, Per Pfeiffer, Karin de Stricker, Ernesto Sparrelid, Carlos Fernández Moro, Frank Mortensen, Anders Riegels Knudsen, Stephen Hamilton-Dutoit, Jörg Kleff, Michael Bau Mortensen, Claus Lindbjerg Andersen, Sönke Detlefsen.
(2025, December). Human Pathology; 168:106024. DOI: 10.1016/j.humpath.2025.106024. PMID: 41421722
118. ctDNA-Guided Therapy in Bladder Cancer - Ready?
Lars Dyrskjøt.
(2025, December). The New England Journal og Medicine; 393:2470-2471. DOI: 10.1056/NEJMe2514185. PMID: 41406450
117. Cross-dataset pan-cancer detection by correlating cell-free DNA fragment coverage with open chromatin sites across cell types
Ludvig Renbo Olsen, Denis Odinokov, Jakob Qvortrup Holsting, Karoline Kondrup, Laura Iisager, Maria Rusan, Simon Buus, Britt Elmedal Laursen, Michael Borre, Mads Ryø Jochumsen, Kirsten Bouchelouche, Amanda Frydendahl, Mads Heilskov Rasmussen, Tenna Vesterman Henriksen, Marijana Nesic, Christina Demuth, Sia Viborg Lindskrog, Iver Nordentoft, Philippe Lamy, Christina Therkildsen, Lars Dyrskjøt, Karina Dalsgaard Sørensen, Claus Lindbjerg Andersen, Anders Jakobsen Skanderup, Søren Besenbacher.
(2025, November). Nature Communications. DOI: 10.1038/s41467-025-66503-3. PMID: 41271753
116. Detection of circulating tumor DNA in colorectal cancer patients using a methylation-specific droplet digital PCR multiplex
Luisa Matos do Canto, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen.
(2025, November). Molecular Oncology. DOI: 10.1002/1878-0261.70161. PMID: 41239188
115. The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
Mette M. Steiniche, Sidsel C. Lindgaard, Inna M. Chen, Julia S. Johansen, Rikke F. Andersen, Torben F. Hansen, Lars H. Jensen, Louise S. Rasmussen, Malene W. Johansen, Morten Ladekarl, Anders K. M. Jakobsen, Karen-Lise G. Spindler.
(2025, November). Clinical Cancer Research; 31(22):4720-4729. DOI: 10.1158/1078-0432.CCR-25-0758. PMID: 40970773
114. Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: A systematic review and meta-analysis
Mette M. Steiniche, Louise B. Callesen, Elizabeth H. Vlk, Lise Ventzel, Signe Timm, Rikke F. Andersen, Sidsel C. Lindgaard, Torben F. Hansen, Morten Ladekarl, Karen-Lise G. Spindler.
(2025, October). The Journal of Liquid Biopsy; 10:100441. DOI: 10.1016/j.jlb.2025.100441. PMID: 41541743
113. Impact of pneumatic tube system transport and blood collection tubes on cell-free DNA analysis of plasma samples
Luisa Matos do Canto, Cecilie Mondrup Jacobsen, Peter H. Nissen, Johanne Andersen Højbjerg, Jonna Skov Madsen, Torben Frøstrup Hansen, Rikke Fredslund Andersen.
(2025, October). Clinical Chemistry and laboratory Medicine; 64(2):332-342. DOI: 10.1515/cclm-2025-0367. PMID: 41468005
112. Development and validation of a methylation-specific droplet digital PCR multiplex for lung cancer detection
Cecilie Mondrup Jacobsen, Peter Hjorth-Hansen, Sara Witting Christensen Wen, Janina Augustenas, Mads Malik Aagaard, Claus Varnum, Ole Hilberg, Torben Frøstrup Hansen, Rikke Fredslund Andersen.
(2025, September). Scientific Reports. DOI: 10.1038/s41598-025-15228-w. PMID: 40897746
111. Unlocking the potential of urine-based liquid biopsy through improved reporting and standardization
Douglas G. Ward, Richard T. Bryan, Aadel A. Chaudhuri, James Hadfield, Jennifer Perez-Boza, Ranske D. M. Steenbergen, Diana M. Vega, Jennifer Whiting, Alexander W. Wyatt, Lars Dyrskjøt.
(2025, September). Nature Reviews Cancer. DOI: 10.1038/s41568-025-00882z. PMID: 40999059
110. Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors
Kristian Egebjerg, Iben Spanggaard, Lise Barlebo Ahlborn, Kristoffer Staal Rohrberg, Laurine Harsloef, Martin Hoejgaard, Ane Yde Schmidt, Ulrik Lassen, Ida Viller Tuxen, Jane Preuss Hasselby, Maria Rossing, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen.
(2025, August). BMC Cancer; 25(1):1272. DOI: 10.1186/s12885-025-14599-7. PMID: 40770324
109. Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer
Jorge Martín-Arana, Francisco Gimeno-Valiente, Tenna Vesterman Henriksen, Blanca García-Micó, Belén Martínez-Castedo, Valentina Gambardella, Carolina Martínez-Ciarpaglini, Brenda Palomar, Marisol Huerta, Daniel G. Camblor, Miguel García Bartolomé, Juan Antonio Carbonell-Asins, Amanda Frydendahl, Kåre Andersson Gotchalck, Tania Fleitas, Roberto Tébar-Martínez, David Moro, Vicente Pla, Leticia Pérez-Santiago, José Martín Arévalo, David Casado, Stephanie Gaciá-Botello, Alejandro Espi, Susana Roselló, Desamparados Roda, Claus Lindbjerg Andersen, Andrés Cervantes, Noelia Tarazona.
(2025, June). Nature cancer; 6(6):1000-1016. DOI: 10.1038/s43018-025-00960-z. PMID: 40301653
108. What the Clinican Needs to Know About Laboratory Analyses of Circulating Tumor DNA
Cecilie Mondrup Jacobsen, Luisa Matos do Canto, Søren Kahns, Torben Frøstrup Hansen, Rikke Fredslund Andersen.
(2025, June). Clinical Colorectal Cancer; 24(2):109-119. DOI: 10.1016/jclcc.2025.01.003. PMID: 39956753
107. Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorecal Cancer
Julian Hamfjord, Tormod Kyrre Guren, Bengt Flimelius, Halfdan Sorbye, Per Pfeiffer, Olav Dajani, Ole Christian Lingjærde, Kjell Magne Tveit, Karen-Lise Garm Spindler, Niels Pallisgaard, Elin H. Kure.
(2025, June). Clinical Colorectal Cancer; 24(2):153-158. DOI: 10.1016/j.clcc.2024.11.004. PMID: 39743478
106. ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach
Lærke Rosenlund, Kasper Guldbrandsen, Lise Barlebo Ahlborn, Martin Bloch, Kristin Skougaard, Elisabeth Albrecht-Beste, Hanne Marie Nellemann, Martin Krakauer, Peter Michael Gørtz, Joan Fledelius, Anne Lerberg Nielsen, Paw Christian Holdgaard, Søren Steen Nielsen, Julie Marie Grüner, Anette Højsgaard, Rene Horsleben Petersen, Lars Borgbjerg Møller, Morten Dahl, Malene Støchkel Frank, Jeanette Haar Ehlers, Zaigham Saghir, MEtte Pøhl, Svetlana Borissova, Lotte Holm Land, Charlotte Kristiansen, Tine McCulloch, Lise Saksø Mortensen, Malene Søby Christophersen, Ole Hilberg, Thor Lind Rasmussen, Signe Høyer Simonsen Schwaner, Christian B. Laursen, Uffe Bodtger, Markus Nowak Lonsdale, Christian Niels Meyer, Oke Gerke, Jann Mortensen, Torben Riis Rasmusen, Karin Hjorthaug, Klaus Richter Larsen, Peter Meldgaard, Barbara Malene Fischer, Boe Sandahl Sørensen.
(2025, May). Lung Cancer: 203:108528. DOI: 10.1016/j.lungcan.2025.108528. PMID: 40220718
105. A prospective study of methylated ctDNA in patients undergoing treatment for liver matastases from colorectal cancer
Louise Raunkilde, Rikke Fredslund Andersen, Caroline Brenner Thomsen, Torben Frøstrup Hansen, Lars Henrik Jensen.
(2025, May). European Journal of Surgical Oncology; 51(5):109586. DOI: 10.1016/j.ejso.2025.109586. PMID: 39847896
104. Timing of ctDNA Analysis Aimed at Guiding Adjuvant Treatment in Colorectal Cancer
Tenna V. Henriksen, Christina Demuth, Amanda Frydendahl, Jesper Nors, Marijana Nesic, Mads H. Rasmussen, Ole H. Larsen, Claudia Jaensch, Uffe S. Løve, Per V. Andersen, Thomas Kolbro, Ole Thorlacius-Ussing, Alessio Monti, Jeppe Kildsig, Peter Bondeven, Nis H. Schlesinger, Lene H. Iversen, Kåre A. Gotschalck, Claus L. Andersen.
(2025, May). Clinical Cancer Research; 31(9):1676-1685. DOI: 10.1158/1078-0432.CCR-24-3200. PMID: 39976513
103. Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation
Sia V. Lindskrog, Trine Strandgaard, Iver Nordentoft, Matthew D. Galsky, Thomas Powles, Mads Agerbæk, Jørgen Bjerggaard Jensen, Catherine Alix-Panabières, Lars Dyrskjøt.
(2025, April). Nature Reviews Urology; 22:590-608. DOI: 10.1038/s41585-025-01023-9. PMID: 40234713
102. Circulating tumor DNA for surveillance in high-risk melanoma patients: A study protocol
Magnús P. B. Obinah, Sarah A. Al-Halafi, Karin Dreisig, Tim S. Poulsen, Christoffer Johansen, Thomas Litman, Stig E. Bojesen, Estrid Høgdall, Annette H. Chakera, Lisbet R. Hölmich.
(2025, February). Acta Oncology; 64:229-233. DOI: 10.2340/1651-226X.2025.42515. PMID: 39930781
101. The role of renal and liver function in clinical ctDNA testing
Jens Bo Conrad, Tenna Vesterman Henriksen, Jesper Berg Nors, Mads Heilskov Rasmussen, Mai-Britt Worm Ørntoft, Nis Hallundbæk Schlesinger, Per Vadgaard Andersen, Kåre Andersson Gotschalck, Claus L. Andersen.
(2025, February). PLOS ONE. DOI: 10.1371/journal.pone.0319194. PMID: 39999130
100. Whole-genome sequencing of cell-free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas
Amanda Frydendahl, Adam J. Widman, Nadia Øgaard, Anushri Arora, DAniel Halmos, Jesper Nors, Johanne Ahrenfeldt, Tenna V. Henriksen, Christina Demuth, Line Raaby, Mads H. Rasmussen, Christina Therkildsen, Dan A. Landau, Claus L. Andersen.
(2025, January). Molecular Oncology. DOI: 10.1002/1878-0261.13803. PMID: 39831554
99. The clinical utility of circulating human papillomavirus across squamous cell carcinomas
Karen-Lise G. Spindler, Anne V. Jakobsen, Jesper G. Eriksen, Lars Fokdal, MArianne Nordsmark, Lise B. J. Thorsen, Karen L. Wind, Anna C. Lefevre, Jens Overgaard.
(2025, January). Acta Oncologica; 61:1-12. DOI: 10.2340/1651-226X.2025.41288. PMID: 39748655
98. Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group
Alexander W. Wyatt, Saskia Litiere, Francois-Clément Bidard, Luc Cabel, Lars Dyrskjøt, Chris A. Karlovich, Klaus Pantel, Joan Patrie, Reena Philip, Hilary S. Andrews, Paz J. Vellanki, Sofie H. Tolmeijer, Xenia Villalobos Alberu, Christian Alfano, Jan Bogaerts, Emiliano Calvo, Alice P. Chen, Rodrigo A. Toledo, Elisabeth G. E. de Vries, Lesley Seymour, Scott A. Laurie, Elena Garralda, RECIST ctDNA workshop gorup.
(2024, November). Clinical Cancer Research; 30(22):5034-5041. DOI: 10.1158/1078-0432.CCR-24-1883. PMID: 39269996
97. Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients
Amanda Frydendahl, Jesper Nors, Mads H. Rasmussen, Tenna V. Henriksen, Marijana Nesic, Thomas Reinert, Danielle Afterman, Tomer Lauterman, Maja Kuzman, Santiago Gonzalez, Dunja Glavas, James Smadback, Dillon Maloney, Jurica Levativ, Michael Yahalom, Ryan Ptashkin, Iman Tavassoly, Zohar Donenhirsh, Eris White, Ravi Kandasamy, Ury Alon, Iver Nordentoft, Sia V. Lindskrog, Lars Dyrskjøt, Claudia Jaensch, Uffe S. Løve, Per V. Andersen, Ole Thorlacius-Ussing, Lene H. Iversen, Kåre A. Gotschalck, Asaf Zviran, Boris Oklander, Claus L. Andersen.
(2024, November). European Journal of Cancer; 211:114314. DOI: 10.1016/j.ejca.2024.114314. PMID: 39316995
96. Biology of Bladder Cancer: From Molecular Insights to Clinical Strategies
Margaret A. Knowles (editor) and Lars Dyrskjøt (editor).
(2024, November). Book. Springer.
95. Circulating methylated HOXA9 tumor DNA as a biomarker for mortality in recurrent breast cancer: An exploratory study
Stine Bakkensen Bruun, Rikke Fredslund Andersen, Jonna Skov Madsen, Torben Frøstrup Hansen, Tomasz Piotr Tabor, Troels Bechmann, Ina Mathilde Kjær.
(2024, October). Oncology Letters; 28(6):581. DOI: 10.3892/ol.2024.14714. PMID: 39421315
94. Evaluating Bioinformatics Processing of Somatic Variant Detection in cfDNA Using Targeted Sequencing with UMIs
Yixin Lin, Mads Heilskov Rasmussen, Mikkel Hovden Christensen, Amanda Frydendahl, Lasse Maretty, Claus Lindbjerg Andersen and Søren Besenbacher.
(2024, October). International Journal of Molecular Sciences; 25(21):11439. DOI: 10.3390/jims252111439. PMID: 39518990
93. DNA methylation markers for sensitive detection of circulating tumor DNA in patients with gastroesophageal cancers
Nadia Øgaard, Cecilie Riis Iden, Sarah Østrup Jensen, Salah M. Mustafa, Emilie aagaard, Jesper B. Bramsen, Lise, B. Ahlborn, Jane Preuss Hasselby, Kristoffer Rohrberg, Michael Achiam, Claus Lindbjerg Andersen, Morten Mau-Sørensen
(2024, October). ESMO Gastrointestinal Oncology; volume 6. DOI: 10.1016/j.esmogo.2024.100104. PMID: 41646953
92. Circulating tumour DNA and risk of recurrence in patients with asymptomatic versus symptomatic colorectal cancer
Nadia Øgaard, Sarah Østrup Jensen, Mai-Britt Worm Ørntoft, Christina Demuth, Mads Heilskov Rasmussen, Tenna Vesterman Henriksen, Jesper Nors, Amanda Frydendahl, Iben Lyskjær, Marijana Nesic, Christina Therkildsen, Jakob Kleif, Mikail Gögenur, Lars Nannestad Jørgensen, Jesper Vilandt, Jakob Benedict Seidelin, Kåre Andersson Gotschalck, Claudia Jaensch, Berit Andersen, Uffe Schou Løve, Ole Thorlacius-Ussing, Per Vadgaard Andersen, Thomas Kolbro, Alessio Monti, Jeppe Kildsig, Peter Bondeven, Nis Hallundbæk Schlesinger, Lene Hjerrild Iversen, Morten Rasmussen, Ismail Gögenur, Jesper Bertram Bramsen, Claus Lindbjerg Andersen.
(2024, October). British Journal of Cancer. DOI: 10.1038/s41416-024-02867-5. PMID: 39390251
91. Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer
Cecilie Riis Iden, Salah Mohammad Mustafa, Nadia Øgaard, Tenna Henriksen, Sarah Østrup Jensen, Lise Barlebo Ahlborn, Kristian Egebjerg, Lene Baeksgaard, Rajendra Singh Garbyal, Mette Kjølhede Nedergaard, Michael Patrick Achiam, Claus Lindbjerg Andersen, Morten Mau-Sørensen.
(2024, October). Gastric Cancer. DOI: 10.1007/s10120-024-01556-9. PMID: 39369091
90. Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers
Medina JE, Annapragada AV, Lof P, Short S, Bartolomucci AL, Mathios D, Koul S, Niknafs N, Noe M, Foda ZH, Bruhm DC, Hruban C, Vulpescu NA, Jung E, Dua R, Canzoniero JV, Cristiano S, Adleff V, Symecko H, van den Broek D, Sokoll LJ, Baylin SB, Press MF, Slamon DJ, Konecny GE, Therkildsen C, Carvalho B, Meijer GA, Andersen CL, Domchek SM, Drapkin R, Scharpf RB, Phallen J, Lok CAR, Velculescu VE.
(2024, September). Cancer Discovery. DOI: 10.1158/2159-8290.CD-24-0393. PMID: 39345137
89. Exploring the biology of ctDNA release in colorectal cancer
Laura Andersen, Judit Kisistók, Tenna V. Henriksen, Jesper B. Bramsen, Thomas Reinert, Nadia Øgaard, Trine B. Mattesen, Nicolai J. Birkbak, Claus L. Andersen
(2024, June). European Journal of Cancer; 207:114186. DOI: 10.1016/j.ejca.2024.114186. PMID: 38943900
88. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment
Adam J. Widman, Minita Shah, Amanda Frydendahl, Daniel Halmos, Cole C. Khamnei, Nadia Øgaard, Srinivas Rajagopalan, Anushri Arora, Aditya Deshpande, William F. Hooper, Jean Quentin, Jake Bass, Mingxuan Zhang, Theopile Langanay, Laura Andersen, Zoe Steinsnyder, Will Liao, Mads Heilskov Rasmussen, Tenna Vesterman Henriksen, Sarah Østrup Jensen, Jesper Nors, Christina Therkildsen, Jesus Sotelo, Ryan Brand, Joshua S. Schiffman, Ronah H. Shah, Alexandre Pellan Cheng, Colleen Maher, Lavinia Spain, Kate Krause, Dennie T. Frederick, Wendie den Brok, Caroline Lohrisch, Tamara Shenkier, Christine Simmons, Diego Villa, Andrew J. Mungall, Richard Moore, Elena Zaikova, Viviana Cerda, Esther Kong, Daniel Lai, Murtaza S. Malbari, Melissa Marton, Dina Manaa, Lara Winterkorn, Karen Gelmon, Margaret K. Callahan, Genevieve Boland, Catherine Potenski, Jedd D. Wolchok, Ashish Saxena, Samra Turajlic, Marcin Imielinski, Michael F. Berger, Sam Aparicio, Nasser K. Altorki, Michael A. Postow, Nicolas Robine, Claus Lindbjerg Andersen, Dan A. Landau.
(2024, June). Nature Medicine. DOI: 10.1038/s41591-024-03040-4. PMID: 38877116
87. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma
Iver Nordentoft, Sia Viborg Lindskrog, Karin Birkenkamp-Demtröder, Santiago Gonzalez, Maja Kuzman, Jurica Levatic, Dunja Glavas, Ryan Ptashkin, James Smadbeck, Danielle Afterman, Tomer Lauterman, Yarin Cohen, Zahar Donenhirsh, Iman Tavassoly, Ury Alon, Amanda Frydendahl, Mads Heilskov Rasmussen, Claus Lindbjerg Andersen, Phillippe Lamy, Michael Knudsen, Lars Dyrskjøt.
(2024, May). European Urology. DOI: 10.1016/j.eururo.2024.05.014. PMID: 38811314
86. Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA
Amanda Frydendahl, Mads Heilskov Rasmussen, Sarah Østrup Jensen, Tenna Vesterman Henriksen, Christina Demuth, Mathilde Diekema, Henrik Jørn Ditzel, Sara Witting Christensen Wen, Jakob Skou Pedersen, Lars Dyrskjøt, Claus Lindbjerg Andersen.
(2024, April). International Journal of Molecular Sciences (MDPI). DOI: 10.3390/ijms25084252. PMID: 38673836
85. Beyond basics - Key mutation selection features for successful tumor-informed ctDNA detection
Marijana Nesic, Mads H. Rasmussen, Tenna V. Henriksen, Christina Demuth, Amanda Frydendahl, Iver Nordentoft, Lars Dyrskjøt, Claus L. Andersen.
(2024, April). International Journal of Cancer. DOI: 10.1002/ijc.34964. PMID: 38623608
84. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach
Lærke Rosenlund Nielsen, Simone Stensgaard, Peter Meldgaard, Boe Sandahl Sørensen.
(2024, February). Cancer Treatment and Research Communications; 39:100802. DOI: 10.1016/j.ctarc.2024.100802. PMID: 38428066
83. KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer - an observational trial. Study protocol
Laura Iisager, Johanne Ahrenfeldt, Anna Krarup Keller, Tommy Kjærgaard Nielsen, Niels Fristrup, Iben Lyskjær.
(2024, February). Acta Oncologica; 63:51-55. DOI: 10.2340/1651-226X.2024.25581. PMID: 38391290
82. Extraction of Cell-Free DNA: Evaluation of Efficiency, Quantity, and Quality
Simone K. Terp, Inge S. Pedersen, Malene P. Stoico.
(2024, February). The Journal of Molecular Diagnostics; S1525-1578(24)00014-X. DOI: 10.1016/j.moldx.2024.01.008. PMID: 38336350
81. Methylated Cell-Free Tumor DNA in Sputum as a Tool for Diagnosing Lung Cancer - A Systematic Review and Meta-Analysis
Sara Witting Christensen Wen, Morten Borg, Signe Timm, Torben Frøstrup Hansen, Anders Jakobsen, Ole Hilberg, Rikke Fredslund Andersen.
(2024, January). Cancers; 16(3):506. DOI: 10.3390/cancers16030506. PMID: 38339257
80. Assessment of circulating biomarkers for detection of lung cancer in a high-risk cohort
Morten Borg, Line Nederby, Sara Witting Christensen Wen, Torben Frøstrup Hansen, Anders Jakobsen, Rikke Fredslund Andersen, Ulla Møller Weinreich, Ole Hilberg.
(2023). Cancer Biomarkers; 36(1):63-69. DOI: 10.3233/CBM-210543. PMID: 36404535
79. Prognostic impact of early ctDNA dynamics during chemotherapy of metastatic cancer
Louise Faaborg, Rikke Fredslund Andersen, Sara Witting Christensen Wen, Caroline B Thomsen, Louise Raunkilde, Torben Frøstrup Hansen, Lars Henrik Jensen, Karina Dahl Steffensen, Anders Jakobsen.
(2023, November). Future Oncology. DOI: 10.2217/fon-2023-0111. PMID: 37965794
78. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer - evaluation in a nationwide Danish cohort
T.V. Henriksen, C. Demuth, A. Frydendahl, J. Nors, M. Nesic, M.H. Rasmussen, T. Reinert, O.H. Larsen, C.Jaensch, U.S. Løve, P.V. Andersen, T. Kolbro, O. Thorlacius-Ussing, A. Monti, M. Gögenur, J. Kildsig, P. Bondeven, N.H. Schlesinger, L.H. Iversen, K.A. Gotschalck, C.L. Andersen.
(2023, November). Annals of Oncology. DOI: 10.1016/j.annonc.2023.11.009. PMID: 37992872
77. Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel
Judit Kisistók, Ditte Sigaard Christensen, Mads Heilskov Rasmussen, Lone Duval, Ninna Aggerholm-Pedersen, Adam Andrzej Luczak, Boe Sandahl Sorensen, Martin Roelsgaard Jakobsen, Trine Heide Oellegaard, Nicolai Juul Birkbak.
(2023, October). Melanoma Research; 33(5):364-374. DOI: 10.1097/CMR.0000000000000903. PMID: 37294123
76. Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group
Louise Bach Callesen, Anders Kindberg Boysen, Rikke Fredslund Andersen, Rikke Beese Dalby, Karen-Lise Garm Spindler.
(2023, October). Scientific Reports; 13(1):18574. DOI: 10.1038/s41598-023-45939-x. PMID: 37903871
75. Liquid Biopsies with Circulating Plasma HPV-DNA Measurements - A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer
Kathrine K. Jakobsen, Simone K. Bendtsen, Niels Pallisgaard, Jeppe Friborg, Giedrius Lekaitis, Christian Grønhøj, Christian von Buchwald.
(2023, October). Clinical Cancer Research; 29(19):3914-3923. DOI: 10.1158/1078-0432.CCR-23-1064. PMID: 37477909
74. Circulating tumor DNA analysis in advanced urothelial carcinoma: Insights from biological analysis and extended clinical follow-up
Sia V. Lindskrog, Karin Birkenkamp-Demtröder, Iver Nordentoft, George Laliotis, Philippe Lamy, Emil Christensen, Derrick Renner, Tine G. Andreasen, Naja Lange, Shruti Sharma, Adam C. ElNaggar, Minetta C. Liu, Himanshu Sethi, Alexey Aleshin, Mads Agerbæk, Jørgen B. Jensen, Lars Dyrskjøt.
(2023, October). Clinical Cancer Research. DOI: 110.1158/1078-0432.CCR-23-1860. PMID: 37782315
73. Field Cancerization is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer
Trine Strandgaard, Iver Nordentoft, Karin Birkenkamp-Demtröder, Liina Salminen, Frederik Prip, Julie Rasmussen, Tine Ginnerup Andreasen, Sia Viborg Lindskrog, Emil Christensen, Philippe Lamy, Michael Knudsen, Torben Steiniche, Jørgen Bjerggaard Jensen, Lars Dyrskjøt.
(2023, September). European Urology; S0302-2838(23)03014-2. DOI: 10.1016/j.eururo.2023.07.014. PMID: 37718188
72. Cell-free DNA approaches for cancer early detection and interception
Jamie E. Medina, Nicholas C. Dracopoli, Peter B. Bach, Anna Lau, Robert B. Scharpf, Gerrit A. Meijer, Claus Lindbjerg Andersen, Victor E. Velculescu.
(2023, September). Journal of Immunotheraoy of Cancer; 11(9):e006013. DOI: 10.1136/jitc-2022-006013. PMID: 37696619
71. ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer-the first interim results from the OPTIMISE study
Louise Bach Callesen, Torben Frøstrup Hansen, Rikke Fredslund Andersen, Niels Pallisgaard, Stine Kramer, Sven Schlander, Søren Rafael Rafaelsen, Anders Kindberg Boysen, Lars Henrik Jensen, Anders Jakobsen, Karen-Lise Garm Spindler.
(2023, September). Acta Oncologica: 22;1-7. DOI: 10.1080/0284186X.2023.2259083 PMID: 37738268
70. Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis
Morten Borg, Sara Witting Christensen Wen, Rikke Fredslund Andersen, Signe Timm, Torben Frøstrup Hansen, Ole Hilberg.
(2023, August). Cancers (Basel); 15(15);3959. DOI: 10.3390/cancers15153959. PMID: 37568774
69. The Importance of Feasibility Assessment in the Design of ctDNA Guided Trials - Results from the OPTIPAL II Study
Luise Bach Callesen, Anders Kindberg Boysen, Christina Søs Audur Andersen, Niels Pallisgaard, Karen-Lise Garm Spindler.
(2023, August). Clinical Colorectal Cancer; S1533-0028(23)00064-5. DOI: 10.1016/j.clcc.2023.07.005. PMID: 37586928
68. NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Sara Witting Christensen Wen, Line Nederby, Rikke Fredslund Andersen, Torben Scjødt Hansen, Christa Haugaard Nyhus, Ole Hilberg, Anders Jakobsen, Torben Frøstrup Hansen
(2023, July). British Journal of Cancer; 129(1):135-142. DOI: 10.1038/s41416-023-02285-z. PMID: 37137997
67. IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer
Emil Christensen, Alexander W Wyatt, Matthew D Galsky, Petros Grivas, Roland Seiler, Roman Nawroth Peter J Goebell, Bernd J Schmitz-Drager, Stephen B Williams, Peter C Black, Ashish M Kamat, Tilman Todenhöfer, Lars Dyrskjøt.
(2023, July). Urologic Oncology; 41(7):318-322. DOI: 10.1016/j.urolonc.2022.11.008. PMID: 36437155
66. 25 years International Bladder Cancer Network (IBCN): The past, the present, and the future25 years International Bladder Cancer Network (IBCN): The past, the present, and the future
Lars Dyrskjøt, Antonia Vlahou, Peter C Black, Michael Droller, H Barton Grossmann, Peter J Goebell, Ashish M Kamat, Roman Nawroth, Roland Seiler, Tilman Todenhöfer, Stephen B Williams, Bernd J Schemitz-Dräger.
(2023, July). Urologic Onvology: 41(7):302-306. DOI: 10.1016/j.urolonc.2022.10.031. PMID: 36437158
65. NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA
Iver Nordentoft, Karin Birkenkamp-Demtröder, Lars Dyrskjøt.
(2023, July). Part of the 'Methods in Molecular Biology' book series (MIMB, volume 2684). DOI: 10.1007/978-1-0716-3291-8_11. PMID: 37410235
64. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A systematic Review
Emanuele Crupi, Tiago Costa de Padua, Laura Marandino, Daniele Raggi, Lars Dyrskjøt, Philippe E Spiess, Guru P Sonpavde, Ashish M Kamat, Andrea Necchi.
(2023, June). European Urology Oncology; S2588-9311(23)00111-6. DOI: 10.1016/j.euo.2023.05.012. PMID: 37330413
63. Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA
Ina Mathilde Kjær, Søren Kahns, Signe Timm, Rikke Fredslund Andersen, Jonna Skov Madsen, Erik Hugger Jakobsen, Thomasz Piotr Tabor, Anders Jakobsen, Troels Bechmann.
(2023, May). Scientific Reports; 13(1):8419. DOI: 10.1038/s41598-023-35362-7. PMID: 37225860
62. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Christopher Abbosh, Alexander M. Frankell, Thomas Harrison, Judit Kisistok, Aaron Garnett, Laura Johnson, Selvaraju veeriah, Mike Moreau, Adrian Chesh, Tafadzwa L. Chaunzwa, Jakob Weiss, Morgan R. Schroeder, Sophia Ward, Kristiana Grigoriadis, Aamir Shahpurwalla, Kevin Litchfield, Clare Puttick, Dhruva Biswas, Takahiro Karasaki, James R. M. Black, Carlos Martínes-Ruiz, Maise Al Bakir, Oriol Pich, Thomas B. K. Watkins, Emilia L. Lim, Ariana Huebner, David A. Moore, Nadia Godin-Heymann, Anne L'Hernault, Hannah Bye, Aaron Odell, Paula Roberts, Fabio Gomes, Akshay J. Patel, Elizabeth Manzano, Crispin T. Hiley, Nicolas Carey, Joan riley, Daniel E. Cook, Darren Hodgson, Daniel Stetson, J. Carl Barrett, Roderik M. Kortlever, Gerard I. Evan, Allan Hacksshaw, Robert D. Daber, Jacqui A. Shaw, Hugo J. W. L. Aerts, Abel Licon, Josh Stahl, Mariam Jamal-Hanjani, TRACERx Consortium, Nicolai J. Birkbak, Nicholas McGranahan, Charles Swanton.
(2023, April). Nature; 616:553-562. DOI 10.1038/s41586-023-05776-4. PMID: 37055640
61. Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors - can we RECIST? Focus on colorectal cancer
Karen-Lise Garm Spindler, Anders Jacobsen.
(2023, April). Therapeutic Advances in Medical Oncology; vol 15:1-11. DOI: 10.1177/17588359231171580. PMID: 37152423
60. DREAMS: deep read-level error model for sequencing data applied to low-frequency variant caling and circualting tumor DNA detection
Mikkel H. Christensen, Simon O. Due, Mads H. Rasmussen, Amanda Frydendahl, Iben Lyskjær, Christina Demuth, Jesper Nors, Kåre A. Gotschalck, Lene H. Iversen, Claus L. Andersen, Jakob Skou Pedersen.
(2023, April). Genome Biology; 24:99. DOI: 10.1186/s13059-023-02920-1. PMID: 37121998
59. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review
Simone Karlsson Terp, Malene Pontoppidan Stoico, Karen Dybkær, Inge Søkilde Pedersen
(2023, February). Clin Epigenet; 15:24. DOI: 10.1186/s13148-023-01440-w. PMID: 36788585
58. Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer
Maibritt Nørgaard, Marianne T Bjerre, Jacob Fredsøe, Søren Vang, Jørgen B Jensen, Bram De Laere, Henrik Grönberg, Michael Borre, Johan Lindberg, Karina D Sørensen.
(2023, February). Clinical Chemistry hvac224. DOI: 10.1093/clinchem/hvac224. PMID: 36762756
57. Cell-free urine-and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancer
Emil Christensen, Iver Nordentoft, Karin Birkenhamp-Demtröder, Sara K. Elbæk, Sia V. Lindskrog, Ann Taber, Tine G. Andreasen, Trine Strandgaard, Michael Knudsen, Philippe Lamy, Mads Agerbæk, Jørgen B. Jensen, Lars Dyrskjøt.
(2023, February). Clinical Cancer Research; 13:CCR-22-3250. DOI: 10.1158/1078-0432.CCR-22-3250. PMID: 36780195
56. ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology
Anders K. M. Jakobsen, Karen-Lise Garm Spindler.
(2023, February). European Journal of Cancer; 180:180-183. DOI: 10.1016/j.ejca.2022.11.039. PMID: 36610263
55. Impact of Whole Genome Doubling on Dettection of Circulating Tumor DNA in Colorectal Cancer
Jonas Kabel, Tenna Vesterman Henriksen, Christina Demuth, Amanda Frydendahl, Mads Heilskov Rasmussen, Jesper Nors, Nicolai J. Birkbak, Anders Husted Madsen, Uffe S. Løve, Per Vadgaard Andersen, Thomas Kolbro, Alessio Monti, Ole Thorlacius-Ussing, Mikail Gögenur, Jeppe Kildsig, Nis Hallundbæk Schlesinger, Peter Bondeven, Lene Hjerrild Iversen, Kåre Andersson Gotschalck, Claus Lindbjerg Andersen.
(2023, February). Cancers; 15(4):1136. DOI: 10.3390/cancers15041136. PMID: 36831479
54. Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non–muscle-invasive Bladder Cancer
Trine Strandgaard; Sia Viborg Lindskrog; Iver Nordentoft; Emil Christensen; Karin Birkenkamp-Dermtröder; Trine Ginnerup Andreasen; Philippe Lamy; Asbjørn Kjær; Daniel Ranti; Yuan-Sho Wang; Christine Bieber; Frederik Prip; Julie Rasmussen; Torben Steiniche; Nicolai Birkbak; John Sfakianos; Amir Horowitz; Jørgen Bjerggaard Jensen; Lars Dyrskjøt.
(2022, December). European Urology; 82(6):646-656. DOI: 10.1016/j.eururo.2022.09.008. PMID: 36210217
53. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis
Callesen LB, Takacova T, Hamfjord J, et al.
(2022, November). Therapeutic Advances in Medical Oncology; 14. DOI: 10.1177/17588359221133171. PMID: 36339929
52. Pre-and Postoperative Circulating Tumour DNA in Patients With Gastrointestinal Stromal Tumour - A Methodological Assessment Study
Brinch CM, Aggerholm-Pedersen N, Poulsen TS, Skovrider-Ruminski W, DE Heer P, Penninga L, Krarup-Hansen A, Hogdall E.
(2022, November). Anticancer Res.; 42(11):5527-5537. DOI: 10.21873/anticanres.16022. PMID: 36288871
51. The Clinical Impact of Methylated Homebox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab
Line Bechsgaard Andersen, Marit Sofie Kjær Mahler, Rikke Fredslund Andersen, Lars Henrik Jensen, Louise Raunkilde.
(2022, September). Cancers; 14(19):4598. DOI: 10.3390/cancers14194598. PMID: 36230519
50. NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
Louise Raunkilde, Torben Frøstrup Hansen, Rikke Fredslund Andersen, Birgitte Havelund, Caroline Brenner Thomsen, Lars Henrik Jensen.
(2022 September). Cancers; 14(18):4459. DOI: 10.3390/cancers14184459. PMID: 36139621
49. Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of advanced Non-Small Cell Lung Cancer patients
Frank M.S., Andersen C.S.A., Ahlborn L.B., Pallisgaard N., Bodtger U., Gehl J.
(2022, September). Cancer Research Communications. DOI: 10.1158/2767-9764.CRC-22-0258
48. Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy
Truelsen CG, Kronborg CS, Sørensen BS, Callesen LB, Spindler KG.
(2022, September). Clinical and Translational Radiation Oncology; 36:9-15. DOI: 10.1016/j.ctro.2022.06.002. PMID: 35733829
47. OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol
Callesen LB, Hansen TF, Andersen RF, Pallisgaard N, Kramer S, Schlander S, Rafaelsen SR, Boysen AK, Jensen LH, Jakobsen A, Spindler KG.
(2022, September). Acta Oncoloca; 12:1-5. DOI: 10.1080/0284186X.2022.2116728. PMID: 36094310
46. ctDNA-Guided Adjuvant Chemotherapy for Colorectal Cancer - Ready for Prime Time
Andersen, CL; Heitzer, E.
(2022, September). Cancer Cell; 40(9):911-913. DOI: 10.1016/j.ccell.2022.08.017. PMID: 36055230
45. Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Callesen LB, Hamfjord J, Boysen AK, Pallisgaard N, Guren TK, Kure EH, Spindler KG.
(2022, August). British Journal of Cancer; 127(3):500-513. DOI: 10.1038/s41416-022-01816-4. PMID: 35440666
44. ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis
Gögenur M, Hadi NA, Qvortrup C, Andersen CL, Gögenur I.
(2022, August). Annals of Surgical Oncology. DOI: 10.1245/s10434-022-12366-7. PMID: 35933546
43. Comparing Single-target and Multitarget Approaches for Postoperative Tumour DNA Detection in Stage II-III Colorectal Cancer Patients
Henriksen, T. V., Reinert, T., Rasmussen, M. H., Demuth, C., Løve, U. S., Madsen, A. H., Gotschalck, K. A., Iversen, L. H., & Andersen, C. L.
(2022, July). Molecular Oncology. DOI: 10.1002/1878-0261.13294. PMID: 35895438
42. Unsupervised Detection of Fragment Length Signatures of Circulating Tumor DINA using non-negative Metrix Factorization
Reanud, G., Nørgaard, M., Lindberg, J., Grönberg, H., De Laere, B., Jensen, J. B., Borre, M., Andersen, C. L., Sørensen, K. D., Maretty, L. & Besenbacher, S.
(2022, July). Elife; 11:e71569. DOI: 10.7554/eLife.71569. PMID: 35894300
41. The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients
Bønløkke S, Stougaard M, Sorensen BS, Booth BB, Høgdall E, Nyvang GB, Lindegaard JC, Blaakær J, Bertelsen J, Fuglsang K, Strube ML, Lenz S, Steiniche T.
(2022, July). Cells; 11(14):2170. DOI: 10.3390/cells11142170. PMID: 35883612
40. Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility
Thomsen, C.B, Juul, A.D., Lefèvre, A.C., Truelsen, C.G., Dizdarevic, E., Ryssel, H., Kjær, I.M., Wind, K.L., Callesen, L.B., Larsen, L.F., Frank, M.S., Andersen, R.F., Spindler, K.G., Jakobsen, A.
(2022, June). Cancer; 128(11):2052-2057. DOI: 10.1002/cncr.34168. PMID: 35302663
39. Error characterization and statistical modeling improves Circulating Tumor DNA detection by droplet digital PCR
Henriksen, T. V., Drue, S. O., Frydendahl, A., Demuth, C., Rasmussen, M. H., Reinert, T., Pedersen, J. S. & Andersen, C. L
(2022, May). Clinical Chemistry; 68(5):657-667. DOI: 10.1093/clinchem/hvab274. PMID: 35030248
38. Circulating Tumor DNA for Prognosis and Postoperative Management after Curative-intent Resection of Colorectal Liver Metastases
Reinert, T., Petersen, L. M. S., Henriksen, T. V., Larsen, M. Ø., Rasmussen, M. H., Johansen, A. F. B., Øgaard, N., Knudsen, M., Nordentoft, I., Vang, S., Krag, S. R. P., Knudsen, A. R., Mortensen, F. V. & Andersen, C. L.
(2022, May). International Journal of Cancer; 150(9):1537-1548. DOI: 10.1002/ijc.33924. PMID: 34994972
37. Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer-A Systematic Review
Wen SWC, Wen J, Hansen TF, Jakobsen A, Hilberg O.
(2022, April). Cancers (Basel); 14(9):2254. DOI: 10.3390/cancers14092254. PMID: 35565384
36. The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
Dizdarevic E, Hansen TF, Jakobsen A.
(2022, April). Cancers (Basel); 14(9):2252. DOI: 10.3390/cancers14092252. PMID: 35565381
35. Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer
Louise Faaborg, Rikke Fredslund Andersen, Marianne Waldstrøm, Jon Røikjær Henriksen, Parvin Adimi, Anders Jakobsen, Karina Dahl Steffensen.
(2022, March). Cancers; 14(7):1766. DOI: 10.3390/cancers14071766. PMID: 35406538
34. Total cell-free DNA measurement in metastatic colorectal cancer with a fast and easy direct fluorescent assay
Callesen LB, Sørensen BS, Pallisgaard N, Laugesen IG, Boysen AK, Spindler KG.
(2022, March). Molecular and Clinical Oncology; 16(3):64. DOI: 10.3892/mco.2022.2497. PMID: 35154704
33. Tumor-agnostic circulating tumor DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: a prospective cohort study
Øgaard N., Reinert T., Henriksen T.V., Frydendahl A., Aagaard E., Ørntoft MB. W., Larsen M.Ø., Knudsen A.R., Mortensen F.V., Andersen C.L.
(2022, March). European Journal of Cancer; 163:163-176. DOI: 10.1016/j.ejca.2021.12.026. PMID: 35074652
32. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study
Pommergaard HC, Yde CW, Ahlborn LB, Andersen CL, Henriksen TV, Hasselby JP, Rostved AA, Sørensen CL, Rohrberg KS, Nielsen FC, Rasmussen A.
(2022, February). Molecular Biology Reports; 49(2):1609-1616. DOI: 10.1007/s11033-021-06962-1. PMID: 34811635
31. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences
Tenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, Thomas Reinert, Francisco Gimeno-Valiente, Juan Antonio Carbonell-Asins, Shruti Sharma, Derrick Renner, Dina Hafez, Desamparados Roda, Marisol Huerta, Susana Roselló, Anders Husted Madsen, Uffe S. Løve, Per Vadgaard Andersen, Ole Thorlacius-Ussing, Lene Hjerrild Iversen, Kåre Andersson Gotschalck, Himanshu Sethi, Alexey Aleshin, Andres Cervantes and Claus Lindbjerg Andersen
(2022, February). Clinical Cancer Research; 28(3):507-517. DOI: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408
30. Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma
Stubbe, B.E.; Henriksen, S.D.; Madsen, P.H.; Larsen, A.C.; Krarup, H.B.; Pedersen, I.S.; Johansen, M.N.; Thorlacius-Ussing, O.
(2021, November). Cancers; 13(22):5717. DOI: 10.3390/cancers13225717. PMID: 34830873
29. Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement
Faaborg L, Fredslund Andersen R, Waldstrøm M, Høgdall E, Høgdall C, Adimi P, Jakobsen A, Dahl Steffensen K.
(2021, November). Clin Chim Acta; 522:152-157. DOI: 10.1016/j.cca.2021.08.020. Epub 2021 Aug 19. PMID: 34419462
28. Investigation of circulating DNA integrity after blood collection
Oriane C., Veyhe S.R., Hansen M.H., Titlestad K., and Nyvold C.G.
(2021, October). BioTechniques; 71(5):550-555. DOI: 10.2144/btn-2020-0167. PMID: 34645292
27. Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer
Wen SWC, Andersen RF, Rasmussen K, Thomsen CB, Hansen TF, Nederby L, Hager H, Jakobsen A, Hilberg O.
(2021, August). Cancers (Basel); 13(16):4223. DOI: 10.3390/cancers13164223. PMID: 34439376
26. Detection and characterization of lung cancer using cell-free DNA fragmentomics
Dimitrios Mathios, Jakob Sidenus Johansen, Stephen Cristiano, Jamie E. Medina, Jillian Phallen, Klaus R. Larsen, Daniel C. Bruhm, Noushin Niknafs, Leonardo Ferreira, Vilmos Adleff, Jia Yuee Chiao, Alessandro Leal, Michael Noe, James R. White, Adith S. Arun, Carolyn Hruban, Akshaya V. Annapragada, Sarah Østrup Jensen, Mai-Britt Worm Ørntoft, Anders Husted Madsen, Beatriz Carvalho, Meike de Wit, Jacob Carey Nicholas C. Dracopoli, Tara Maddala, Kenneth C. Fang, Anne-Renne Hartman, Patrick M. Forde, Valsamo Anagonostou, Julie R. Brahmer, Remon J. A. Fijneman, Hans Jørgen Nielsen, Gerrit A. Meijer, Claus Lindbjerg Andersen, Anders Mellemgaard, Stig E. Bojesen, Robert B. Scharphf, Victor E. Velculescu.
(2021, August). Nature Communications; 12(1):5060. DOI: 10.38/s41467-021-24994-w. PMID: 34417454
25. A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies
Jensen SG, Epistolio S, Madsen CL, Kyneb MH, Riva A, Paganotti A, Barizzi J, Petersen RK, Børgesen M, Molinari F, Boldorini R, Lorenzen J, Sørensen E, Christensen UB, Høgdall E, Frattini M.
(2021, June). PLoS One; 16(6):e0253687. DOI: 10.1371/journal.pone.0253687. PMID: 34166445
24. Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma - An external validation study
Henriksen SD, Stubbe BE, Madsen PH, Johansen JS, Jensen BV, Hansen CP, Johansen MN, Pedersen IS, Krarup H, Thorlacius-Ussing O.
(2021, May). Pancreatology; 8:S1424-3903(21)00154-X. DOI: 10.1016/j.pan.2021.05.003. PMID: 33994313
23. The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus
Lefèvre AC, Pallisgaard N, Kronborg C, Wind KL, Krag SRP, Spindler KG.
(2021, May). Cancers; 13(10):2451. DOI: 10.3390/cancers13102451. PMID: 34070045
22. Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma-A Literature Update
Henriksen SD, Thorlacius-Ussing O.
(2021, April). Epigenomes; 9;5(2):8. DOI: 10.3390/epigenomes5020008. PMID: 34968295
21. Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival
Jakobsen A, Andersen RF, Hansen TF, Jensen LH, Faaborg L, Steffensen KD, Thomsen CB, Wen SWC.
(2021, April). European Journal of Cancer,;149:128-133. DOI: 10.1016/j.ejca.2021.03.006. PMID: 33857886
20. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer
Mai-Briit Worm Ørntoft, Sarah Østrup Jensen, Nadia Øgaard, Tenna Vesterman Henriksen, Linnea Ferm, Ib Jarle Christensen, Thomas Reinert, Ole Halfdan Larsen, Hans Jørgen Nielsen, Claus Lindbjerg Andersen.
(2021, April). International Journal of Cancer; 148(7):1668-1675. DOI: 10.1002/ijc.33434. PMID: 33320961
19. Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer
Tarpgaard LS, Andersen PV, Øgaard N, Demuth C, Andersen CL, Pfeiffer P.
(2021, March). Annals of Oncololy; 32(6):805-806. DOI: 10.1016/j.annonc.2021.03.001. PMID: 33727198
18. The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer
Wen SWC, Andersen RF, Hansen TF, Nyhus CH, Hager H, Hilberg O, Jakobsen A.
(2021, February). Translational Lung Cancer Reserch; 10(2):855-865. DOI: 10.21037/tlcr-20-826. PMID: 33718027
17. Quantifying sequencing error and effective sequencing depth of liquid biopsy NGS with UMI error correction
Frank, M.S., Fuß, J., Steiert, T.A., Streleckiene, G., Gehl, J., Forster, M.
(2021, January). BioTechniques; 70(4). DOI: 10.2144/btn-2020-0124. PMID: 33512245
16. Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer
Young GP, Symonds EL, Nielsen HJ, Ferm L, Christensen IJ, Dekker E, van der Vlugt M, Mallant-Hent RC, Boulter N, Yu B, Chan M, Tevz G, LaPointe LC, Pedersen SK.
(2021, January). Clin Epigenetics; 13(1):14. DOI: 10.1186/s13148-020-00999-y. PMID: 33478584
15. Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma
Wen SWC, Andersen RF, Petersen LMS, Hager H, Hilberg O, Jakobsen A, Hansen TF.
(2020, December). Cancers; 12(12):3728. DOI: 10.3390/cancers12123728. PMID: 33322500
14. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer
Ørntoft MW, Jensen SØ, Øgaard N, Henriksen TV, Ferm L, Christensen IJ, Reinert T, Larsen OH, Nielsen HJ, Andersen CL.
(2020, December). International Journal of Cancer; 148(7):1665-1675. DOI: 10.1002/ijc.33434. PMID: 33320961
13. Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer
Boysen AK, Pallisgaard N, Andersen CSA, Spindler KG.
(2020, August). Acta Oncologia; 59(12):1424-1429. DOI: 10.1080/0284186X.2020.1806357. PMID: 32790489
12. Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion
Sarah Ø Jensen, Nadia Øgaard, Hans Jørgen Nielsen, Jesper B Bramsen, Claus L Andersen.
(2020, July). Clinical Chemistry; 66(7):925-933. DOI: 10.1093/clinchem/hvaa100. PMID: 32460325
11. Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer
Caroline Brenner Thomsen, Torben F. Hansen, Rikke F. Andersen, Jan Lindebjerg, Lars H. Jensen, Anders Jakobsen.
(2020, May). Therapeutic Advances in Medical Oncology. DOI: 10.1177/1758835920918472. PMID: 32518596
10. The effect of surgical trauma on circulating free DNA levels in cancer patients - implications for studies of circulating tumor DNA
Henriksen TV, Reinert T, Christensen E, Sethi H, Birkenkamp-Demtröder K, Gögenur M, Gögenur I, Zimmermann BG; IMPROVE Study Group, Dyrskjøt L, Andersen CL..
(2020, May). Molecular Oncology; 14(8):1670-1679. DOI: 10.1002/1878-0261.12729. PMID: 32471011
9. Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations
Nygård L, Ahlborn LB, Persson GF, Chandrananda D, Langer JW, Fischer BM, Langer SW, Gabrielaite M, Kjær A, Rosenfeld N, Mouliere F, Østrup O, Vogelius IR, Bentzen SM.
(2020, April). PLoS One; 15(4). DOI: 10.1371/journal.pone.0231884. PMID: 32343749. PMCID: PMC7188247
8. Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER)
Skougaard K, Østrup O, Guldbrandsen K, Sørensen B, Meldgaard P, Saghir Z, Gørtz P, Lonsdale MN, Frank MS, Gerke O, Rychwicka-Kielek BA, Persson G, Land LH, Schytte T, Bodtger U, Skuladottir H, Søgaard J, Nielsen SS, Rasmussen TR, Fischer BM.
(2020, March). Clinical Lung Cancer; 21(2):e61-e64. DOI: 10.1016/j.cllc.2019.11.002. PMID: 31839533
7. Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer
Caroline Brenner Thomsen, Rikke F. Andersen, Jan Lindebjerg, Torben F. Hansen, Lars Henrik Jensen, Anders Jakobsen.
(2019, December). JCO Precision Oncology. DOI: 10.1200/PO.18.00162. PMID: 35100675
6. NPC Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer
Lars Henrik Jensen, René Olesen, Lone Noergaard Petersen, Anders Kindberg Boysen, Rikke Fredslund Andersen, Jan Lindebjerg, Lise Nottelmann, Caroline Emilie Brenner Thomsen, Birgitte Mayland Havelund, Anders Jakobsen, Torben Frøstrup Hansen.
(2019, October). Cancers; 11(11):1649. DOI: 10.3390/cancers11111649. PMID: 31731482
5. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients with Stages I to III Colorectal CancerAnalysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients with Stages I to III Colorectal Cancer
Thomas Reinert, Tenna Vesterman Henriksen, Emil Christensen, Shruti Charma, Raheleh Salari, Himanshu Sethi, Michael Knudsen, Iver Nordentoft, Hsin-Ta Wu, Antony S. Tin, Mads Heilskov Rasmussen, Søren Vang, Svetlana Shchegrova, Amanda Frydendahl Boll Johansen, Ramya Srinivasan, Zoe Assaf, Mustafa Balcioglu, Alexander Olson, Scott Dashner, Dina Hafez, Samantha Navarro, Shruti Goel, Matthew Rabinowitz, Paul Billings, Stymir Sigurjonsson, Lars Dyrskjøt, Ryan Swenerton, Alexey Aleshin, Søren Laurberg, Anders Husted Madsen, Anne-Sofie Kannerup, Katrine Stribolt, Søren Palmelund Krag. Lene H. Iversen, Kåre Gotschalck Sunesen, Cheng-Ho Jimmy Lin, Bernhard G. Zimmermann, Claus Lindbjerg Andersen.
(2019, August). JAMA Oncology; 5(8):124-1131. DOI: 10.1001/jamaoncol.2019.0528. PMID: 31070691
4. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study
Nørøxe DS, Østrup O, Yde CW, Ahlborn LB, Nielsen FC, Michaelsen SR, Larsen VA, Skjøth-Rasmussen J, Brennum J, Hamerlik P, Poulsen HS, Lassen U.
(2019, July). Oncotarget; 10(43):4397-4406. DOI: 10.18632/oncotarget.27030. PMID: 31320993. PMCID: PMC6633897
3. Toward liquid biopsies in cancer treatment: Application of circulating tumor DNA
Barlebo Ahlborn L, Østrup O.
(2019, May). APMIS; 127(5):329-336. DOI: 10.1111/apm.12912. PMID: 30784124
2. IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer - intervention trial 2. Study protocol
Jesper Nors, Tenna Vesterman Henriksen, Kåre Andersson Gotschalck, Therese Juul, Jes Søgaard, Lene Hjerrild Iversen, Claus Lindbjerg Andersen.
(2020, March). Acta Oncologica; 59(3):336-341. DOI: 10.1080/0284186X.2019.1711170. PMID: 31920137
1. Application of cell-free DNA for genomic tumor profiling: A feasibility study
Ahlborn LB, Rohrberg KS, Gabrielaite M, Tuxen IV, Yde CW, Spanggaard I, Santoni-Rugiu E, Nielsen FC, Lassen U, Mau-Sorensen M, Østrup O.
(2019, February). Oncotarget; 10(14):1388-1398. DOI: 10.18632/oncotarget.26642. PMID: 30858924. PMCID: PMC6402712
Do you have any publications to share?
Contact the center with your publication. In this way you contribute to the shared list of publications done about ctDNA in Denmark.
Contact
E-mail: ctdna@clin.au.dk
ADDRESS FOR THE SECRETARIAT
Science Center Skejby, MOMA
Brendstrupgårdsvej 21, build. A
8200 Aarhus N
CONTACT